Trial Profile
A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Leber's hereditary optic atrophy
- Focus Adverse reactions; Therapeutic Use
- Acronyms ReSIGHT
- Sponsors Stealth BioTherapeutics
- 24 Jan 2020 Status changed from active, no longer recruiting to completed.
- 14 Aug 2019 According to a Stealth BioTherapeutics media release, data from the trial and open label extension phase was presented at the United Mitochondrial Disease Foundation Symposium 2019 and at the 14th meeting of the European Neuro-ophthalmology Society.
- 30 Apr 2019 According to a Stealth BioTherapeutics media release, results from the study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting.